Press and Ad-hoc Releases

Dr. Selwyn Ho appointed new CEO of Medigene

SHOW RELEASE

Medigene provides Q1 2022 update

SHOW RELEASE

Medigene publication details augmentation of PRAME-specific TCR-4 by PD1-41BB switch receptor

SHOW RELEASE

Medigene participates at upcoming conferences

SHOW RELEASE

Medigene provides results for fiscal year 2021 and outlook

SHOW RELEASE

BioNTech and Medigene announce global collaboration to advance T cell receptor immunotherapies against cancer

SHOW RELEASE

Medigene reports preliminary efficacy and immune monitoring data of Phase I of Phase I/II MDG1011 trial in blood cancers

SHOW RELEASE

Medigene achieves positive preliminary results in Phase I of Phase I/II trial of TCR-T therapy MDG1011 in blood cancers

SHOW RELEASE

New safety data shows Medigene's inducible system produces correctly-paired T cell receptors only

SHOW RELEASE

Medigene, IRICoR, and University of Montréal expand analyses of potentially novel cancer antigens

SHOW RELEASE

Medigene provides Q3 2021 update

SHOW RELEASE

Data validating TCR-Ts targeted to ovarian tumor-specific "dark matter" antigen to be presented at SITC

SHOW RELEASE

Medigene participates at upcoming conferences

SHOW RELEASE

Medigene receives USD2 m milestone payment from Roivant/Cytovant and improves financial forecast for 2021

SHOW RELEASE

Neoantigens shared amongst patients and indications broaden the applicability of T cell-based cancer immunotherapies

SHOW RELEASE